Veritas Pharma Inc.

A discovery and IP development company, advancing the science behind medical Cannabis

Company Overview

Recent News on Veritas Pharma Inc.

 

“Cannevert scientist accepted to attend Bedrocan’s Masterclass on medicinal cannabis in Leiden, The Netherlands”

Latest News

Investors Presentation

Dedicated to discovering new cannabis cultivars for disease-specific actions

View PDF

In The Media

“Here’s why Veritas Pharma Inc is one of the most exciting stocks in medical marijuana right now”

Read More

About Veritas Pharma

The medical marijuana industry is projected to have substantial growth over the next few years and Veritas is among the first to employ a comprehensive scientific approach behind medical marijuana claims. Our mission is to develop the most effective proprietary cannabis strains for specific disease conditions providing doctors and patients with conclusive scientific evidence for the recommendation and use of medical marijuana with confidence.  

Veritas has formed an exclusive partnership and investment in Cannevert Therapeutics, a high-level research and development company, with its main office on the University of British Columbia (UBC) campus. Cannevert has brought together a highly accredited team of pharmacologists, anaesthetists and chemists with proven track records of success in drug development in both academia and industry. This alliance will provide Veritas with the required technical ability to achieve its goals in research, development and commercialization. 

Veritas, through its wholly owned subsidiary Sechelt Organic Marijuana Inc., aims to become a license producer through an ACMPR license, which its application is pending with Health Canada since July 4th, 2014. 

Veritas Approach

The Veritas Newsletter

Enter your email to receive news alerts and updates from Veritas Pharma.

You have Successfully Subscribed!